Rapamycin-conditioned dendritic cells activated with monophosphoryl lipid A promote allograft acceptance <i>in vivo</i>

dc.contributor.authorCampos-Acuna, Javier
dc.contributor.authorPerez, Francisco
dc.contributor.authorNarvaez, Edgar
dc.contributor.authorCampos-Mora, Mauricio
dc.contributor.authorGajardo, Tania
dc.contributor.authorCatalan, Diego
dc.contributor.authorAguillon, Juan C.
dc.contributor.authorPino-Lagos, Karina
dc.date.accessioned2025-01-23T21:37:38Z
dc.date.available2025-01-23T21:37:38Z
dc.date.issued2015
dc.description.abstractAim: To date, there is no human dendritic cell (DC) based therapy to prevent allograft rejection in transplanted patients. Here, we evaluate a potential protocol using a murine in vivo transplant model. Materials & methods: We generated murine bone marrow-derived DCs (BM-DCs), modulated with rapamycin (Rapa) and activated with monophosphoryl lipid A (Rapamycin-treated and monophosphoryl lipid A-matured DCs [Rapa-mDCs]). DCs phenotype was evaluated by flow cytometry, cytokine production by ELISA and their T-cell stimulatory ability was tested in co-cultures with CD4(+) T cells. Using an in vivo skin graft model, we evaluated DCs tolerogenicity. Results: In vitro, Rapa-mDCs exhibit a semi-mature phenotype given by intermediate levels of co-stimulatory molecules and cytokines, and inhibit CD4(+) T-cell proliferation. In vivo, skin-grafted mice treated with Rapa-mDCs show high allograft survival, accumulation of Foxp3(+) Tregs and cytokine pattern modification. Conclusion: Rapa-mDCs re-educate the inflammatory microenvironment, promoting skin-allograft survival.
dc.fuente.origenWOS
dc.identifier.doi10.2217/imt.14.116
dc.identifier.eissn1750-7448
dc.identifier.issn1750-743X
dc.identifier.urihttps://doi.org/10.2217/imt.14.116
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/101579
dc.identifier.wosidWOS:000350395600004
dc.issue.numero2
dc.language.isoen
dc.pagina.final110
dc.pagina.inicio101
dc.revistaImmunotherapy
dc.rightsacceso restringido
dc.subjectcellular therapy
dc.subjectdendritic cells
dc.subjectregulatory T cells
dc.subjecttolerance
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleRapamycin-conditioned dendritic cells activated with monophosphoryl lipid A promote allograft acceptance <i>in vivo</i>
dc.typeartículo
dc.volumen7
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files